AN-2718 is a member of a new class of antifungals, benzoxaboroles, which inhibit fungal growth by blocking protein synthesis. AN-2718 is being developed for the topical treatment of tinea pedis including the hard to treat mocassin-type, which at present is only treatable with oral antifungals. AN-2718 inhibits an essential protein synthesis enzyme, leucyl-transfer RNA synthetase, or LeuRS. AN-2718 Inhibits LeuRS by the OBORT mechanism of trapping tRNALEU in the editing site of LeuRS. AN-2718 has good MIC90 activity against the dermatophytes, T. rubrum and T. mentagrophytes, which supports its use as a topical agent to treat tinea pedis. AN-2718 has been used in trials studying Tinea Pedis, but its development has been discontinued.